Global Glaucoma Surgery Devices Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Glaucoma Surgery Devices Market Analysis

The glaucoma surgery devices market is rapidly evolving, driven by increasing global glaucoma prevalence and advancements in surgical technology. Glaucoma, a leading cause of irreversible blindness, requires effective management to lower intraocular pressure (IOP). Traditional surgical approaches, such as trabeculectomy, are being supplemented by minimally invasive glaucoma surgeries (MIGS) and advanced devices. MIGS offers patients quicker recovery times and fewer complications, making them an attractive option for many.  Recent advancements in glaucoma surgery devices include the development of micro-invasive stents, drainage implants, and laser systems designed for precise targeting of IOP. Devices such as the iStent, iTrack Advance, and MINIject are revolutionizing treatment by providing safer, more effective options. These technologies have also made procedures more accessible to a broader patient base, contributing to the growing demand for glaucoma surgery devices.  The market is further driven by the rise in strategic collaborations, regulatory approvals, and the increasing focus on reducing surgical risks and improving outcomes. Leading companies such as Novartis, Glaukos, AbbVie, and Johnson & Johnson are investing heavily in innovation to enhance device performance. As a result, the glaucoma surgery devices market is poised for significant growth, offering patients more advanced treatment options for better long-term eye health.

Glaucoma Surgery Devices Market Size

The global glaucoma surgery devices market size was valued at USD 3.01 billion in 2024 and is projected to reach USD 5.97 billion by 2032, with a CAGR of 8.94% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Glaucoma Surgery Devices Market Trends

“Increasing Shift towards Micro-Invasive Devices”

The glaucoma surgery devices market is witnessing significant growth, driven by the increasing demand for minimally invasive glaucoma surgeries (MIGS) and technological advancements. One key trend is the shift towards micro-invasive devices that offer quicker recovery times and fewer complications compared to traditional methods. For instance, the iStent Inject from Glaukos has gained FDA approval as a MIGS option, offering patients a safer, less invasive alternative to trabeculectomy. These devices are designed to reduce intraocular pressure (IOP) more effectively with reduced risk of side effects, making them highly attractive for both patients and surgeons. The advancement in glaucoma drainage devices and laser systems, such as the iTrack Advance canaloplasty system, further reflects this trend of improving surgical precision and minimizing recovery periods. As MIGS devices continue to evolve, the market is expanding, with key players such as Novartis and AbbVie leading the way, creating more innovative solutions to manage glaucoma with better patient outcomes.

Report Scope and Glaucoma Surgery Devices Market Segmentation 

Glaucoma Surgery Devices Market Definition

Glaucoma surgery devices are specialized medical instruments used in the surgical treatment of glaucoma, a condition characterized by increased intraocular pressure (IOP) that can damage the optic nerve and lead to blindness. These devices are designed to lower IOP by either improving the drainage of fluid from the eye or reducing fluid production.

Glaucoma Surgery Devices Market Dynamics

Drivers

• Rising Prevalence of Glaucoma

The rising prevalence of glaucoma is a significant driver for the growth of the glaucoma surgery devices market. As the global population ages, the number of people affected by glaucoma, a leading cause of irreversible blindness, continues to increase. According to the World Health Organization (WHO), glaucoma affects an estimated 80 million people worldwide, with this number projected to rise to 112 million by 2040, primarily due to aging populations. This escalating prevalence creates a larger patient base, amplifying the demand for effective treatment options. As glaucoma often progresses without noticeable symptoms until significant damage has occurred, surgical interventions become necessary to preserve vision. With advances in minimally invasive surgery techniques, such as MIGS (Minimally Invasive Glaucoma Surgery) devices such as the iStent Inject and drainage implants such as iTrack Advance, there is a greater focus on providing timely and effective solutions for these patients. The increasing number of glaucoma patients worldwide directly influences the demand for advanced glaucoma surgery devices, making it a key market driver.

• Rising Technological Advancements in Glaucoma Surgeries

Technological advancements in the field of glaucoma surgery have become a key driver for the growth of the glaucoma surgery devices market. Innovations in minimally invasive glaucoma surgeries (MIGS), such as the development of microstents, drainage devices, and laser systems, have significantly improved treatment outcomes by reducing intraocular pressure (IOP) with fewer complications and quicker recovery times compared to traditional surgical methods. For instance, the iStent Inject, a microstent approved by the FDA, has shown impressive results in clinical trials, reducing IOP by over 20% in many patients and offering a safer, more effective alternative to trabeculectomy. Similarly, the iTrack Advance canaloplasty system offers a minimally invasive way to treat glaucoma while preserving the eye's natural anatomy, providing significant long-term pressure reduction. According to a study published in the Journal of Glaucoma, MIGS procedures, including the use of devices such as iStent Inject, result in faster recovery times and fewer postoperative complications, which makes them more appealing to both patients and surgeons. These technological innovations are enhancing patient outcomes and fueling market growth by increasing the adoption of advanced, minimally invasive glaucoma devices.

Opportunities

• Rising Healthcare Expenditures

Rising healthcare expenditures, particularly in emerging markets, are creating significant opportunities for the glaucoma surgery devices market. As countries such as India, China, and Brazil experience rapid economic growth, healthcare spending has risen substantially, enabling the adoption of advanced surgical devices for treating glaucoma. For instance, in China, the healthcare sector has seen a steady increase in government funding and private investments aimed at improving medical infrastructure and access to advanced treatments. The Chinese government has also prioritized addressing chronic diseases such as glaucoma, leading to increased demand for innovative solutions such as microstents and drainage implants. In addition, with the growing middle class in these regions, there is an increasing willingness to invest in premium healthcare products that offer better outcomes. According to a report by the World Bank, healthcare spending in emerging markets is expected to grow by 5-7% annually, providing a robust market opportunity for companies offering advanced glaucoma surgery devices. This trend presents significant growth potential, particularly for companies such as Glaukos, AbbVie, and iSTAR Medical, which are strategically positioning their products to tap into these expanding markets.

• Rise in Investment By Key Players

The rise in investment by key players in the glaucoma surgery devices market presents a significant growth opportunity. Leading companies are increasingly focusing on expanding their product portfolios and improving device technology to meet the growing demand for effective glaucoma treatments. For instance, AbbVie invested USD 60 million to acquire iSTAR Medical, a company known for its innovative MINIject device, which is a minimally invasive glaucoma surgery (MIGS) solution designed to reduce intraocular pressure. This strategic investment underscores the increasing commitment by major players to innovate and strengthen their position in the market. Similarly, Glaukos Corporation has been expanding its product line, with devices such as the iStent Inject gaining widespread adoption, reflecting the industry's focus on developing safer, more effective surgical options. As the global glaucoma burden rises, these investments in cutting-edge technology offer companies an opportunity to capture a larger share of the growing market, particularly in emerging regions where healthcare infrastructure is improving. Thus, the rise in investments by key players is opening new avenues for market expansion and technological innovation in glaucoma surgery devices.

Restraints/Challenges

• High Costs of Glaucoma Surgery Devices

The high costs of glaucoma surgery devices pose a significant market challenge, especially for patients in lower-income regions or those lacking comprehensive healthcare coverage. Advanced glaucoma surgical procedures, such as trabeculectomy or the implantation of microstents, often require expensive devices, specialized tools, and skilled surgical expertise. For instance, the implantation of a glaucoma drainage device, such as the Ahmed valve or Baerveldt implant, can cost thousands of dollars, not including the associated costs of surgery, post-operative care, and long-term monitoring. In many countries, particularly in developing regions, healthcare systems may not cover these expenses, making such treatments inaccessible to a large portion of the population. This disparity in access to treatment exacerbates health inequities and limits the potential market for these devices in certain regions, thereby slowing overall market growth. As a result, high treatment costs remain a key barrier for both patients and healthcare providers, making affordability and health insurance coverage crucial factors in expanding the reach of glaucoma surgery devices globally.

• Adverse Effects and Associated Risks

Adverse effects and risks associated with glaucoma surgery devices remain a significant challenge in the market, as potential complications can make patients hesitant to undergo surgical procedures. While surgical technologies, such as microstents and drainage implants, have advanced, risks such as infection, bleeding, and deterioration in vision can still occur. For instance, post-operative infections can lead to delayed healing, while excessive scarring after procedures such as trabeculectomy may lead to increased intraocular pressure or even blindness. These complications impact the patient's quality of life and result in longer recovery times, requiring additional treatments and follow-up visits. The fear of these adverse outcomes deters some patients from opting for surgery and may lead to reluctance in adopting newer surgical techniques. As a result, these risks create a barrier to the widespread adoption of glaucoma surgery devices, ultimately limiting market growth as patients and healthcare providers seek safer, less invasive alternatives such as eye drops or laser treatments. This underscores the challenge of balancing innovation with patient safety and the need for continuous improvements in surgical technologies to mitigate risks.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Glaucoma Surgery Devices Market Scope

The market is segmented on the basis of product, target, surgery type, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Glaucoma Drainage Device
  • Valves
  • Glaucoma Drainage Implant
  • Glaucoma Tube Shunts
  • Stents
• Traditional Surgery Devices
  • Scalpel
  • Forceps
  • Ophthalmic Scissors
  • Punch
  • Sutures
  • Surgical Drapes
  • Microcatheter
  • Others
• Diamond Knives
• Laser Systems
• Others

Target

• Trabecular Meshwork
• Suprachoroidal Space
• Others

Surgery Type

• Conventional Glaucoma Surgeries
  • Trabeculectomy
  • Tube Shunt Surgery
• Minimally Invasive Glaucoma Surgeries
  • Trabecular Meshwork Bypass
  • Suprachoroidal Space Implants
  • Subconjunctival Space Implants
  • Schlemm’s Canal Implants
  • Gonioscopy-assisted Transluminal Trabeculectomy
  • Endocyclophotocoagulation
• Laser Surgery
  • Trabeculoplasty
  • Iridotomy
  • Cyclophotocoagulation

End-User

• Eye Hospitals
• Ophthalmology Clinics
• Outpatient Surgical Centres

Glaucoma Surgery Devices Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, target, surgery type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the glaucoma surgery devices market, driven by the presence of major industry players and improved reimbursement policies. Public health initiatives such as Eye America and Vision US have further contributed to raising awareness about glaucoma, encouraging early diagnosis and treatment. Additionally, the region benefits from quicker product availability and widespread access to advanced medical technologies. These factors collectively support the market’s growth and dominance in North America.

Asia-Pacific is expected to experience significant growth in the glaucoma surgery devices market, driven by the increasing shift towards minimally invasive procedures for glaucoma treatment. The region is also witnessing rapid technological advancements, enhancing the effectiveness and precision of glaucoma surgery devices. As healthcare infrastructure improves, more patients are gaining access to innovative treatments, further fueling market demand. The combination of evolving surgical techniques and cutting-edge technology positions Asia-Pacific as a key growth region in the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Glaucoma Surgery Devices Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Glaucoma Surgery Devices Market Leaders Operating in the Market Are:

• Novartis AG (Switzerland)
• Glaukos Corporation (U.S.)
• Abbott (U.S.)
• New World Medical, Inc. (U.S.)
• Johnson & Johnson Services Inc. (U.S.)
• Bausch + Lomb (U.S.)
• TOPCON CORPORATION (Japan)
• Lumenis Be Ltd. (Israel)
• AbbVie Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• NIDEK CO., LTD (Japan)
• Haag-Streit Group (Switzerland)
• Essilor (France)
• Ziemer Ophthalmic Systems AG (Switzerland)
• Carl Zeiss Meditec AG (Germany)
• Sonomed Escalon (U.S.)
• HumanOptics Holding AG (Germany)
• BVI (U.S.)

Latest Developments in Glaucoma Surgery Devices Market

• In April 2023, Nova Eye Medical Ltd. obtained FDA 510(k) clearance for its canaloplasty device, iTrack Advance, designed to lower intraocular pressure (IOP) in adult patients with primary open-angle glaucoma
• In August 2022, Glaukos Corp. received FDA 510(k) clearance for iStent Infinite, a standalone device for reducing elevated IOP in primary open-angle glaucoma patients
• In July 2022, iSTAR Medical entered a strategic partnership with AbbVie to expand AbbVie's portfolio of glaucoma treatments, offering patients additional care options
• In June 2022, AbbVie announced a USD 60 million deal for the rights to acquire iSTAR Medical, a Belgian firm developing the minimally invasive MINIject glaucoma device, now in a U.S. premarket approval study. AbbVie is collaborating on the development and commercialization of the device
• In June 2022, Iridex Corporation secured regulatory approval from China’s National Medical Products Administration (NMPA) to market and sell its Cyclo G6 platform for glaucoma treatment

SKU-63256